The incidence and risk factors of infusion-related reactions to rituximab for treating B cell malignancies in a single tertiary hospital

Oncology (Switzerland)

Volumn 86, Issue 3, 2014, Pages 127-134

  Jung, Jae Woo ^a,c   Kang, Hye Ryun ^a,b   Lee, Se Hoon ^b   Cho, Sang Heon ^a,b  

^a Seoul National University College of Medicine   (South Korea)

^b Seoul National University Hospital   (South Korea)

^c Chung Ang University College of Medicine   (South Korea)

Author keywords

Adverse effects; Drug hypersensitivity; Monoclonal antibody; Risk factors; Rituximab

Indexed keywords

CORTICOSTEROID; RITUXIMAB;

ABDOMINAL CRAMP; ADULT; ANGIONEUROTIC EDEMA; ARTICLE; B CELL LYMPHOMA; BRONCHOSPASM; BURKITT LYMPHOMA; CANCER PATIENT; CARDIOVASCULAR DISEASE; CHILL; CLINICAL FEATURE; CONSCIOUSNESS DISORDER; CONTROLLED STUDY; DYSPNEA; FATIGUE; FEMALE; FEVER; FOLLICULAR LYMPHOMA; HIGH RISK PATIENT; HOT FLUSH; HUMAN; HYPOTENSION; INCIDENCE; INFUSION RELATED REACTION; LARGE CELL LYMPHOMA; LARYNX EDEMA; MAJOR CLINICAL STUDY; MALE; MANTLE CELL LYMPHOMA; NAUSEA; NEUROTOXICITY; NOSE OBSTRUCTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; PRURITUS; RASH; RHINITIS; RISK FACTOR; SHIVERING; SIDE EFFECT; TERTIARY CARE CENTER; URTICARIA; VOMITING; ABDOMINAL PAIN; CANCER CHEMOTHERAPY; CANCER FATIGUE; CANCER INCIDENCE; CANCER RISK; CHEMOTHERAPY INDUCED EMESIS; DIARRHEA; DIZZINESS; DRUG DOSE INCREASE; DRUG ERUPTION; DRUG SAFETY; ELECTRONIC MEDICAL RECORD; FAINTNESS; HEADACHE; HEART ARREST; HEART ARRHYTHMIA; LYMPHOCYTOMA; SEIZURE; TACHYCARDIA; THORAX PAIN; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC AGENTS; B-LYMPHOCYTES; DRUG HYPERSENSITIVITY; FEMALE; HUMANS; INCIDENCE; INFUSIONS, INTRAVENOUS; LYMPHOMA, B-CELL; MALE; MIDDLE AGED; REPUBLIC OF KOREA; RISK FACTORS; TERTIARY CARE CENTERS;

EID: 84893207734     PISSN: 00302414     EISSN: 14230232     Source Type: Journal    
DOI: 10.1159/000357711     Document Type: Article

References (28)

1. Maloney DG, Liles TM, Czerwinski DK, Waldichuk C, Rosenberg J, Grillo-Lopez A, Levy R: Phase I clinical trial using escalating singledose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. Blood 1994; 84: 2457-2466.
2. Kimby E: Tolerability and safety of rituximab (MabThera). Cancer Treat Rev 2005; 31: 456-473.
3. Lenz HJ: Management and preparedness for infusion and hypersensitivity reactions. Oncologist 2007; 12: 601-609.
4. Dillman RO: Infusion reactions associated with the therapeutic use of monoclonal antibodies in the treatment of malignancy. Cancer Metastasis Rev 1999; 18: 465-471.
5. McLaughlin P, Hagemeister FB, Grillo-Lopez AJ: Rituximab in indolent lymphoma: The single-Agent pivotal trial. Semin Oncol 1999; 26: 79-87.
6. Brown BA, Torabi M: Incidence of infusionassociated reactions with rituximab for treating multiple sclerosis: A retrospective analysis of patients treated at a US centre. Drug Saf 2011; 34: 117-123.
7. Hauser SL, Waubant E, Arnold DL, Vollmer T, Antel J, Fox RJ, Bar-Or A, Panzara M, Sarkar N, Agarwal S, et al: B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 2008; 358: 676-688.
8. Cohen SB, Emery P, Greenwald MW, Dougados M, Furie RA, Genovese MC, Keystone EC, Loveless JE, Burmester GR, Cravets MW, et al: Rituximab for rheumatoid arthritis refractory to anti-Tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 2006; 54: 2793-2806.
9. Merrill JT, Neuwelt CM, Wallace DJ, Shanahan JC, Latinis KM, Oates JC, Utset TO, Gordon C, Isenberg DA, Hsieh HJ, et al: Efficacy and safety of rituximab in moderately-To-severely active systemic lupus erythematosus: The randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum 2010; 62: 222-233.
10. Edwards IR, Biriell C: Harmonisation in pharmacovigilance. Drug Saf 1994; 10: 93-102.
11. Meyboom RH, Hekster YA, Egberts AC, Gribnau FW, Edwards IR: Causal or casual? The role of causality assessment in pharmacovigilance. Drug Saf 1997; 17: 374-389.
12. Kang SP, Saif MW: Infusion-related and hypersensitivity reactions of monoclonal antibodies used to treat colorectal cancer-identification, prevention, and management. J Support Oncol 2007; 5: 451-457.
13. Grillo-Lopez AJ, Hedrick E, Rashford M, Benyunes M: Rituximab: Ongoing and future clinical development. Semin Oncol 2002; 29: 105-112.
14. Kemp SF, Lockey RF, Simons FE: Epinephrine: The drug of choice for anaphylaxis-A statement of the World Allergy Organization. Allergy 2008; 63: 1061-1070.
15. Breslin S: Cytokine-release syndrome: Overview and nursing implications. Clin J Oncol Nurs 2007; 11: 37-42.
16. Byrd JC, Murphy T, Howard RS, Lucas MS, Goodrich A, Park K, Pearson M, Waselenko JK, Ling G, Grever MR, et al: Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity. J Clin Oncol 2001; 19: 2153-2164.
17. Byrd JC, Waselenko JK, Maneatis TJ, Murphy T, Ward FT, Monahan BP, Sipe MA, Donegan S, White CA: Rituximab therapy in hematologic malignancy patients with circulating blood tumor cells: Association with increased infusion-related side effects and rapid blood tumor clearance. J Clin Oncol 1999; 17: 791-795.
18. Winkler U, Jensen M, Manzke O, Schulz H, Diehl V, Engert A: Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDECC2B8). Blood 1999; 94: 2217-2224.
19. Vultaggio A, Matucci A, Nencini F, Pratesi S, Parronchi P, Rossi O, Romagnani S, Maggi E: Anti-infliximab IgE and non-IgE antibodies and induction of infusion-related severe anaphylactic reactions. Allergy 2010; 65: 657-661.
20. Peereboom DM, Donehower RC, Eisenhauer EA, McGuire WP, Onetto N, Hubbard JL, Piccart M, Gianni L, Rowinsky EK: Successful re-Treatment with taxol after major hypersensitivity reactions. J Clin Oncol 1993; 11: 885-890.
21. Sehn LH, Donaldson J, Filewich A, Fitzgerald C, Gill KK, Runzer N, Searle B, Souliere S, Spinelli JJ, Sutherland J, et al: Rapid infusion rituximab in combination with corticosteroid-containing chemotherapy or as maintenance therapy is well tolerated and can safely be delivered in the community setting. Blood 2007; 109: 4171-4173.
22. Salar A, Casao D, Cervera M, Pedro C, Calafell M, Abella E, Alvarez-Larran A, Besses C: Rapid infusion of rituximab with or without steroid-containing chemotherapy: 1-yr experience in a single institution. Eur J Haematol 2006; 77: 338-340.
23. Vogel WH: Infusion reactions: Diagnosis, assessment, and management. Clin J Oncol Nurs 2010; 14:E10-E21.
24. Murase T, Yamaguchi M, Suzuki R, Okamoto M, Sato Y, Tamaru J, Kojima M, Miura I, Mori N, Yoshino T, et al: Intravascular large B-cell lymphoma (IVLBCL): A clinicopathologic study of 96 cases with special reference to the immunophenotypic heterogeneity of CD5. Blood 2007; 109: 478-485.
25. Saif MW: Hypersensitivity reactions associated with oxaliplatin. Expert Opin Drug Saf 2006; 5: 687-694.
26. Rituxan prescribing information. http:// www.gene.com/gene/products/ information/ pdf/rituxan-prescribing.pdf (accessed July 2013).
27. Weiss RB: Hypersensitivity reactions. Semin Oncol 1992; 19: 458-477.
28. Wilke H, Glynne-Jones R, Thaler J, Adenis A, Preusser P, Aguilar EA, Aapro MS, Esser R, Loos AH, Siena S: Cetuximab plus irinotecan in heavily pretreated metastatic colorectal cancer progressing on irinotecan: MABEL Study. J Clin Oncol 2008; 26: 5335-5343.